So you arrive back home from e year travelling with friends, you return home to find a new arrival at your home. He is a teenager but is apparently your brother. Your parents inform you that he has spent most of his life in a psychiatric unit due to a accident which left him brain damaged, so is unable to care for himself or even talk and understand what is going on around him. He has gotten to old to stay at the unit and the doctors do not want to move him to an adult wars as they feel he would benefit better from being home.
So how will you react? Will you welcome your long lost brother with open arms or want nothing to do with him?
------
So I'm looking for a brother or sister to be the family member that comes home to find there brother, I will be playing the long lost brother.
If this gains interest I will write up the character sheets.
~There's only now, there's only this, forget regret, or life is yours to miss~ - RENT
~ If at first you don't succed, Destroy all evidence that you tried ~
ScienceDaily (July 8, 2012) ? Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
Their findings will be published online in the July 8, 2012 issue of Nature Medicine.
After observing mice without genes responsible for development of an immune cell called T helper cell 17 (TH17), researchers found that these mice had significant resistance to melanoma tumor growth, suggesting that blockade of the TH17 cell pathway favored tumor inhibition. The researchers also noticed that the mice expressed high amounts of interleukin-9.
"These were unexpected results, which led us to examine a possible contribution of interleukin-9 to cancer growth suppression." said Purwar.
The researchers next treated melanoma-bearing mice with T helper cell 9 (TH9), an immune cell that produces interleukin-9. They saw that these mice also had a profound resistance to melanoma growth. This is the first reported finding showing an anti-tumor effect of TH9 cells.
Moreover, the researchers were able to detect TH9 cells in both normal human blood and skin, specifically in skin-resident memory T cells and memory T cells in peripheral blood mononuclear cells. In contrast, TH9 cells were either absent or present at very low levels in human melanoma. This new finding paves the way for future studies that will assess the role of interleukin-9 and TH9 cells in human cancer therapy.
"Immunotherapy of cancer is coming of age, and there have been exciting recent results in patients with melanoma treated with drugs that stimulate the immune system," said Kupper. "We hope that our results will also translate to the treatment of melanoma patients, but much work still needs to be done."
According to the researchers, other cell-signaling molecules have been used in treating melanoma; however, this study is the first to investigate the role of interleukin-9 in melanoma tumor immunity.
Melanoma is the most dangerous form of skin cancer. The National Cancer Institute estimates that in 2012, there will be more than 76,000 new cases of melanoma in the United States and 9,180 deaths. Melanoma is curable if recognized and treated early.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Brigham and Women's Hospital, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
Rahul Purwar, Christoph Schlapbach, Sheng Xiao, Hong Soon Kang, Wassim Elyaman, Xiaodong Jiang, Anton M Jetten, Samia J Khoury, Robert C Fuhlbrigge, Vijay K Kuchroo, Rachael A Clark, Thomas S Kupper. Robust tumor immunity to melanoma mediated by interleukin-9?producing T cells. Nature Medicine, 2012; DOI: 10.1038/nm.2856
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Have you actually viewed Converse Pas Cher an auto racing occasion on tv and was envious at the activities in the driver Although there are many times that excellent auto racing events choose spot exactly where you?ll find no mishaps or crashes, the second a driver dies or crashes the thought about how dangerous the sport of auto racing is must strike Converse Pas Cher residence to most people. Nevertheless, several average people are fired up regarding the thought that they get whenever they consider it might be doable to acquire the chance to journey in a racecar, substantially less generate in one. On the other hand, there are really actual colleges across the United states of america and somewhere else that can allow you have the feeling of the life time. For anyone who is bound and determined to experience an automobile racing vehicle from your own driver?s seat, check out several of the possibilities that these companies will assist you to with!
1. Ken Lowe Drag Racing College
This skilled automobile racing college is actually located in Australia, but the key point of the school is always to educate students ways to drive one of the genuine automobile racing autos which have been employed in automobile races all through the globe. Even though Converse All Star this school is very common and gives an once-in-a-lifetime likelihood to become in a position to carry out and push in a true auto racing automobile, there?s individualized support for each university student that will come for the college. You will discover also different ranges in the lessons that a single is able to obtain into also. By way of example, there?s a Licensing Program too as a Supercharged Course that will educate you the fundamentals, and sophisticated maneuvers, of driving in an automobile racing automobile. You can find also smaller course measurements at the Ken Lowe Drag Racing School to ensure that far more emphasis might be within the schooling and driver from the vehicle itself.
2. Outstanding Adventures
This firm and business enterprise Converse Pas Cher just isn?t situated outdoors the United states of america, but situated proper in Sarasota, Florida. Just as there are actually different levels that could allow you to study about auto racing using the college that is outlined above, so also are there amounts within the Unbelievable Adventures School. For starters and those who would just like a speedy encounter inside the mind of an automobile racing specialist, there?s an Introduction to Brief Track Auto Racing. Even though this lesson expenses a fairly penny, drivers with the car racing cars study the fundamentals of managing the vehicle, too as the fundamentals involved with all the race monitor at the same time! If you are looking for an thrilling time then this really is the place to be! Certainly, for those who want extra sophisticated practice with their auto racing skills there is certainly generally the Competition Driving Program, also because the Sophisticated Program that is definitely also referred to as the ?Race to Win.?
3. Pro-Drive College
Last although not the very least, college students are able to learn the ins and outs of driving a skilled racecar in the Portland, Oregon Pro-Drive School. This automobile racing school will even offer you the chance of a life time to just take more than the wheel in the vehicle in automobile racing that you have often dreamed of.
Irrespective of in case you pick to go to Oregon, Florida, or Australia, though, chances are that you will have the only real chance that a single actually will get to sit at the rear of the wheel of a real-life auto racing vehicle. These schools are so common, even though, they actually train hundreds of folks and students Converse for each 12 months!
Official Converse Basse presents a lot of discounted Converse right now with Super fast Shipping, Safeguarded Payment & Terrific Customer Service from Converse Homme Shop.
The harpsichord will be highlighted as Summerfest continues its 2012 season, ?Invitation to the Dance.?
Harpsichordist Marie Rubis Bauer of Omaha, Neb., will perform music by Jean-Philippe Rameau, and she?ll be joined by the Summerfest ensemble for a work by Bohuslav Martin?. The concerts are at 7 p.m. July 14 at White Recital Hall, 4949 Cherry St., and at 5 p.m. July 15 at Country Club Christian Church, 6101 Ward Parkway. Also on the program is music by Ferenc Farkas and Ern? Dohn?nyi.The harpsichord is not to everyone?s taste. The great English conductor Sir Thomas Beecham had an especially strong distaste for the instrument. He once described its sound as ?two skeletons copulating on a corrugated tin roof.? But if any composer can turn someone into a fan of the harpsichord, it?s Rameau.It amazes me that Rameau is not as well known and appreciated as Johann Sebastian Bach and Antonio Vivaldi. Rameau wrote some of the most tuneful and toe-tapping music of the baroque era. Rubis Bauer will perform selections from Rameau?s Pi?ces de clavecin, a three-book collection of dazzling, kaleidoscopic music for harpsichord.In a brilliant bit of programming, Rubis Bauer and the Summerfest ensemble will follow Rameau with Promenades for flute, violin and harpsichord by Czech composer Martin?. Although much of his music is informed by the rhythms of his native Bohemia, Martin? lived in Paris in the 1920s and 30s and absorbed its elegant musical culture. Promenades has a Gallic flair and a sprightly Baroque quality that will complement Rameau very nicely. The second half of the program features music by two 20th century Hungarian composers. It will open with Old Hungarian Dances of the 17th century for woodwind quintet by Farkas, and the concert will conclude with the Sextet in C major, Op. 37 for piano, violin, viola, cello, clarinet and horn by Dohn?nyi. The selection has classical form and a romantic sound, but the final movement takes off in a jazzy direction with a lively tune that wouldn?t have been out of place in a 1930s nightclub. For tickets, call 816-235-6222 or visit . ?The Great Caruso?With his big, beautiful voice and outsized charisma, Mario Lanza was often referred to as ?the new Caruso.? In fact, there seemed to be a cosmic connection between the two singers. Lanza was born the year Enrico Caruso died, and he was baptized by a priest named Caruso. When Lanza was growing up, his father would play Enrico Caruso?s records on the Victrola for hours, and Lanza absorbed what he heard. Eventually, Lanza became America?s most popular opera singer, and his biggest hit was ?Vesti la giubba? from ?Pagliacci,? which also happened to be the aria that made Caruso a household name.Who better than Lanza, then, to portray Caruso on the big screen? You?ll have a chance to see Lanza in ?The Great Caruso? when the Performing Arts Series of Johnson County Community College presents a free screening of the Hollywood blockbuster at 7 p.m. Wednesday at Yardley Hall, Johnson County Community College.The MGM film, Lanza?s third starring vehicle, was hugely popular when it came out in 1951. The demands of moviemaking, however, left Lanza no time for a legitimate opera career on the stage, and this hurt him with opera critics who increasingly regarded him as a dilettante. But critics be damned. ?The Great Caruso? wowed audiences. It is hardly an accurate portrayal of Caruso?s life and suffers, like so many Hollywood films of that era, from a treacly sentimentality. But it also has virtues that are often lacking in contemporary films, like over-the-top operatic music and romance. The film supposedly inspired Placido Domingo, Jose Carreras and Luciano Pavarotti to pursue opera careers. Pavarotti has spoken of going to see Lanza?s films and then coming home and acting them out as he watched himself in the mirror.Audiences rarely have a chance to see ?The Great Caruso? on the big screen, so this film was an inspired choice by Emily Behrmann, general manager of the Performing Arts Series.?Over the past two years, we?ve focused on classic musicals on our summer movie series, but this year, I wanted to find a couple of films that connected more to the performing arts and famous performers,? she said. ?Some of our moviegoers last summer suggested Mario Lanza?s films, which I thought was a great idea. So ?The Great Caruso? fulfilled their wish and mine.?Regarding Caruso, Lanza said, ?Imagine, all my life this man is my idol. All of a sudden I get the chance to play him on the screen. I have to be Caruso. I don?t want to be just an actor who looks like the man, singing his songs. No, I want to be this man, as he grows older, gets heavier.?Like Caruso, Lanza worked hard and played hard and flamed out early. Caruso, a heavy smoker and eater, died of peritonitis at the age of 48. Lanza also had Promethean appetites and struggled with his weight and went on alcoholic binges. He died from a pulmonary embolism at 38 while he was preparing for his debut in Rome in ?Pagliacci.? ?Turn your distress and tears into jest, your pain and sobbing into a funny face ? Ah! Laugh, clown, at your broken love!?Laugh, clown, laugh.?
You can reach Patrick Neas at PatrickNeas@gmail.com.
Researchers discover molecule in immune system that could help treat dangerous skin cancerPublic release date: 8-Jul-2012 [ | E-mail | Share ]
Contact: Marjorie Montemayor-Quellenberg mmontemayor-quellenberg@partners.org 617-534-2208 Brigham and Women's Hospital
BOSTON, MAResearchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
Their findings will be published online in the July 8, 2012 issue of Nature Medicine.
After observing mice without genes responsible for development of an immune cell called T helper cell 17 (TH17), researchers found that these mice had significant resistance to melanoma tumor growth, suggesting that blockade of the TH17 cell pathway favored tumor inhibition. The researchers also noticed that the mice expressed high amounts of interleukin-9.
"These were unexpected results, which led us to examine a possible contribution of interleukin-9 to cancer growth suppression." said Purwar.
The researchers next treated melanoma-bearing mice with T helper cell 9 (TH9), an immune cell that produces interleukin-9. They saw that these mice also had a profound resistance to melanoma growth. This is the first reported finding showing an anti-tumor effect of TH9 cells.
Moreover, the researchers were able to detect TH9 cells in both normal human blood and skin, specifically in skin-resident memory T cells and memory T cells in peripheral blood mononuclear cells. In contrast, TH9 cells were either absent or present at very low levels in human melanoma. This new finding paves the way for future studies that will assess the role of interleukin-9 and TH9 cells in human cancer therapy.
"Immunotherapy of cancer is coming of age, and there have been exciting recent results in patients with melanoma treated with drugs that stimulate the immune system," said Kupper. "We hope that our results will also translate to the treatment of melanoma patients, but much work still needs to be done."
According to the researchers, other cell-signaling molecules have been used in treating melanoma; however, this study is the first to investigate the role of interleukin-9 in melanoma tumor immunity.
Melanoma is the most dangerous form of skin cancer. The National Cancer Institute estimates that in 2012, there will be more than 76,000 new cases of melanoma in the United States and 9,180 deaths. Melanoma is curable if recognized and treated early.
###
This research was supported by the United States National Institutes of Health (R01 AI-41707, R01 AI-097128, P50 CA-093683, R01-AR-056720, R03-MH-095529 and Z01-ES-101586) and The Skin Cancer Foundation.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs nearly 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving nearly 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $625 million in funding. BWH continually pushes the boundaries of medicine, including building on its legacy in organ transplantation by performing the first face transplants in the U.S. in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies, OurGenes and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Researchers discover molecule in immune system that could help treat dangerous skin cancerPublic release date: 8-Jul-2012 [ | E-mail | Share ]
Contact: Marjorie Montemayor-Quellenberg mmontemayor-quellenberg@partners.org 617-534-2208 Brigham and Women's Hospital
BOSTON, MAResearchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
Their findings will be published online in the July 8, 2012 issue of Nature Medicine.
After observing mice without genes responsible for development of an immune cell called T helper cell 17 (TH17), researchers found that these mice had significant resistance to melanoma tumor growth, suggesting that blockade of the TH17 cell pathway favored tumor inhibition. The researchers also noticed that the mice expressed high amounts of interleukin-9.
"These were unexpected results, which led us to examine a possible contribution of interleukin-9 to cancer growth suppression." said Purwar.
The researchers next treated melanoma-bearing mice with T helper cell 9 (TH9), an immune cell that produces interleukin-9. They saw that these mice also had a profound resistance to melanoma growth. This is the first reported finding showing an anti-tumor effect of TH9 cells.
Moreover, the researchers were able to detect TH9 cells in both normal human blood and skin, specifically in skin-resident memory T cells and memory T cells in peripheral blood mononuclear cells. In contrast, TH9 cells were either absent or present at very low levels in human melanoma. This new finding paves the way for future studies that will assess the role of interleukin-9 and TH9 cells in human cancer therapy.
"Immunotherapy of cancer is coming of age, and there have been exciting recent results in patients with melanoma treated with drugs that stimulate the immune system," said Kupper. "We hope that our results will also translate to the treatment of melanoma patients, but much work still needs to be done."
According to the researchers, other cell-signaling molecules have been used in treating melanoma; however, this study is the first to investigate the role of interleukin-9 in melanoma tumor immunity.
Melanoma is the most dangerous form of skin cancer. The National Cancer Institute estimates that in 2012, there will be more than 76,000 new cases of melanoma in the United States and 9,180 deaths. Melanoma is curable if recognized and treated early.
###
This research was supported by the United States National Institutes of Health (R01 AI-41707, R01 AI-097128, P50 CA-093683, R01-AR-056720, R03-MH-095529 and Z01-ES-101586) and The Skin Cancer Foundation.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs nearly 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving nearly 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $625 million in funding. BWH continually pushes the boundaries of medicine, including building on its legacy in organ transplantation by performing the first face transplants in the U.S. in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies, OurGenes and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.